Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4596

Sort by

Sort Order Select

Journal Articles

Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects

Kristina Maas-Bauer, Juliane K. Lohmeyer, Toshihito Hirai, Teresa Lopes Ramos, Furqan M. Fazal, Ulrike M. Litzenburger, Kathryn E. Yost, Jessica V. Ribado, Neeraja Kambham, Arielle S. Wenokur, Po-Yu Lin, Maite Alvarez, Melissa Mavers, Jeanette Baker, Ami S. Bhatt, Howard Y. Chang, Federico Simonetta, Robert S. Negrin

Blood (2021) 138 (10): 858–870.

https://doi.org/10.1182/blood.2021010887

Published: 2021

Includes: Supplemental data

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

Acute GVHD: do we trust our gut?

Yi-Bin Chen

Blood (2021) 137 (11): 1447–1448.

https://doi.org/10.1182/blood.2020009596

Published: 2021

Journal Articles

Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients

Raffaella Greco, Rosamaria Nitti, Nicasio Mancini, Renée Pasciuta, Francesca Lorentino, Maria Teresa Lupo-Stanghellini, Maria Chiara Barbanti, Nicola Clementi, Fabio Giglio, Daniela Clerici, Sarah Marktel, Andrea Assanelli, Matteo G. Carrabba, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Massimo Clementi, Fabio Ciceri

Blood (2021) 137 (11): 1556–1559.

https://doi.org/10.1182/blood.2020007158

Published: 2021

Journal Articles

Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease

Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd Stollenwerk, Richard Komorowski, Alicia López, Rosa María Tolón, Julian Romero, Cecilia J. Hillard, William R. Drobyski

Blood (2021) 137 (9): 1241–1255.

https://doi.org/10.1182/blood.2020004871

Published: 2021

Includes: Supplemental data

Journal Articles

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Blood (2021) 137 (8): 1090–1103.

https://doi.org/10.1182/blood.2020005628

Published: 2021

Includes: Supplemental data

Journal Articles

Into the subcrypt zone: CD8 T cells in GI acute GVHD

Roman M. Shapiro, John Koreth

Blood (2021) 137 (5): 587–588.

https://doi.org/10.1182/blood.2020008910

Published: 2021

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Introduction to a review series on pathophysiology and treatment of acute GVHD

Robert Zeiser

Blood (2020) 136 (4): 375–376.

https://doi.org/10.1182/blood.2019004271

Published: 2020

Journal Articles

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Carlijn Voermans, Mette D. Hazenberg

Blood (2020) 136 (4): 410–417.

https://doi.org/10.1182/blood.2019000951

Published: 2020

Journal Articles

Microbiome-intestine cross talk during acute graft-versus-host disease

Hind Rafei, Robert R. Jenq

Blood (2020) 136 (4): 401–409.

https://doi.org/10.1182/blood.2019000950

Published: 2020

Journal Articles

Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease

Tomomi Toubai, John Magenau

Blood (2020) 136 (4): 429–440.

https://doi.org/10.1182/blood.2019000953

Published: 2020

Journal Articles

Cytokines and costimulation in acute graft-versus-host disease

Geoffrey R. Hill, Motoko Koyama

Blood (2020) 136 (4): 418–428.

https://doi.org/10.1182/blood.2019000952

Published: 2020

Journal Articles

HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation

Effie W. Petersdorf, Philip Stevenson, Mats Bengtsson, Dianne De Santis, Valerie Dubois, Ted Gooley, Mary Horowitz, Katharine Hsu, J. Alejandro Madrigal, Mari Malkki, Caroline McKallor, Yasuo Morishima, Machteld Oudshoorn, Stephen R. Spellman, Jean Villard, Mary Carrington

Blood (2020) 136 (3): 362–369.

https://doi.org/10.1182/blood.2020005743

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano, Regis Peffault de Latour

Blood (2020) 135 (20): 1721–1722.

https://doi.org/10.1182/blood.2020005364

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat steroid-refractory acute graft-versus-host disease

Paul J. Martin

Blood (2020) 135 (19): 1630–1638.

https://doi.org/10.1182/blood.2019000960

Published: 2020

Includes: Supplemental data

Journal Articles

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

Blood (2020) 135 (15): 1287–1298.

https://doi.org/10.1182/blood.2019003186

Published: 2020

Includes: Supplemental data

Journal Articles

High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity

Tom Erkers, Bryan J. Xie, Laura J. Kenyon, Brian Smith, Mary Rieck, Kent P. Jensen, Xuhuai Ji, Marina Basina, Samuel Strober, Robert S. Negrin, Holden T. Maecker, Everett H. Meyer

Blood (2020) 135 (11): 814–825.

https://doi.org/10.1182/blood.2019001903

Published: 2020

Includes: Supplemental data

NARROW

Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Acute GVHD: do we trust our gut?

Microbiome markers are early predictors of acute GVHD in allogeneic hematopoietic stem cell transplant recipients

Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses

Into the subcrypt zone: CD8 T cells in GI acute GVHD

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Introduction to a review series on pathophysiology and treatment of acute GVHD

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

Microbiome-intestine cross talk during acute graft-versus-host disease

Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease

Cytokines and costimulation in acute graft-versus-host disease

HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation

Ruxolitinib for steroid-resistant acute GVHD

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

How I treat steroid-refractory acute graft-versus-host disease

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only